SecBot SecBot

VIR drug pipeline

Vir Biotechnology, Inc. · 5 rated drugs
$9.58
−3.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.2%
1-day, median of 1 event
IV rank
19
IV 73% · HV 70%
Rated drugs
5
2 bullish · 3 neutral
Phase 3 trials
2
0 with results posted

Upcoming catalysts

3 dated
  1. Nov 2026
    tobevibart
    Phase 2 primary completion
  2. Dec 2026
    tobevibart
    Phase 3 primary completion
  3. Dec 31, 2026
    tobevibart
    Phase 3 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketIf Phase 3 ECLIPSE 1 results are positive, regulatory filings could follow in 2027, with potential FDA approval in 2027-2028 given the Breakthrough Therapy designation enabling expedited review.

elebsiran Updated Nov 6

What to watch

The pivotal Phase 3 ECLIPSE 1 topline results for elebsiran plus tobevibart in chronic hepatitis delta will be presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Positive data would support regulatory filings and validate the combination against bulevirtide; negative or mixed results would severely damage the company's lead program thesis. The stock surged ~11% on November 6 ahead of the readout, reflecting anticipation.

Bull case
  • Elebsiran plus tobevibart has FDA Breakthrough Therapy Designation and EMA PRIME Designation for chronic hepatitis delta, enabling expedited regulatory review.
  • Phase 2 SOLSTICE data showed high rates of undetectable HDV RNA and ALT normalization, with durable 96-week suppression published in NEJM.
  • The Norgine licensing deal (up to ~$645M) validates the program and provides a commercial partner for Europe, Australia and New Zealand.
Bear case
  • Bulevirtide (Hepcludex) was FDA-approved in May 2026 for chronic hepatitis delta, establishing a competitive benchmark that elebsiran/tobevibart must beat or match.
  • The Phase 3 ECLIPSE 1 trial is open-label (not blinded), which can introduce bias and may limit the strength of the evidence for regulators.
  • Multiple institutional investors trimmed or exited positions in Q2 2026, including Citadel (-52.8%), Millennium (-90.2%), and Jacobs Levy (-90.5%), signaling skepticism.
▲ bullish
Impact
PhasePhase 3
Time to marketIf ECLIPSE 1 data is positive, Vir could file for regulatory approval in 2027, with potential FDA decision in 2028. The program has FDA Breakthrough Therapy and EMA PRIME designations, which could accelerate review.

tobevibart Updated Nov 6

What to watch

The pivotal Phase 3 ECLIPSE 1 topline data is being presented at AASLD on November 8, 2026 (tomorrow), with an investor call on November 9 at 8:30 AM ET. Positive results showing non-inferiority or superiority versus bulevirtide/deferred treatment could drive significant upside given the $21 mean analyst price target (90%+ implied upside). Negative or mixed data would likely pressure the stock given the program's centrality to Vir's valuation. ECLIPSE 2 and ECLIPSE 3 readouts are expected in Q1 2027.

Bull case
  • Phase 2 SOLSTICE data showed 66% of combination patients achieved undetectable HDV RNA at week 48 with no grade 3+ treatment-related adverse events, published in NEJM
  • Monthly subcutaneous dosing offers a significant convenience advantage over Gilead's Hepcludex (bulevirtide), which requires daily injections
  • FDA Breakthrough Therapy and EMA PRIME designations signal regulatory interest and could accelerate review
Bear case
  • Gilead's Hepcludex (bulevirtide) was FDA-approved in May 2026 as the first CHD treatment, establishing an incumbent therapy and potentially limiting tobevibart's addressable market
  • Elevated short-sale volume (z-score 2.02 vs own history) and insider sales by the General Counsel (under 10b5-1 plan) suggest some near-term skepticism
  • ECLIPSE 1 is an open-label trial versus deferred treatment, not a blinded placebo-controlled design, which may raise questions about the data quality
● neutral
Impact
PhasePhase 1
Time to marketVIR-5500 is in Phase 1 dose expansion. Pivotal Phase 3 trials are anticipated to begin in 2027. Even with Fast Track designation, approval is likely several years away, assuming successful development.

VIR-5500 Updated Nov 6

What to watch

VIR-5500 is an early-stage but promising PSMA-targeted T-cell engager with strong Phase 1 data and a deep-pocketed partner in Astellas. The next meaningful catalyst is updated Phase 1 dose expansion data, but no date has been set. For Vir Biotechnology as a whole, the more immediate binary event is the ECLIPSE 1 Phase 3 topline readout for hepatitis delta expected in Q4 2026, which is likely to drive near-term share price action more than VIR-5500 news.

Bull case
  • Early Phase 1 data showed compelling efficacy: 82% PSA50 response rate and 45% objective response rate at higher doses in heavily pretreated patients who had exhausted other options, with no dose-limiting toxicities observed.
  • The dual-masked PRO-XTEN technology appears to mitigate the cytokine release syndrome risk that has plagued other T-cell engagers, potentially giving VIR-5500 a best-in-class safety profile.
  • The Astellas collaboration (up to $1.7B total, with $335M upfront/near-term) provides substantial validation, co-development funding, and a large-pharma commercialization partner with a track record in prostate cancer (Xtandi).
Bear case
  • VIR-5500 is still in Phase 1 with a small sample size (58 patients in dose escalation); efficacy and safety need confirmation in larger, randomized trials.
  • Phase 3 trials are not expected to start until 2027, meaning no near-term binary catalyst and years until potential commercialization.
  • Competition in PSMA-targeted therapies is intensifying: Novartis's Pluvicto (radioligand therapy) is already approved, and other T-cell engagers (e.g., GSK's GSK5458514) are entering the clinic.
● neutral
Impact
PhasePhase 1/2
Time to marketVIR-5818 is in Phase 1/2 with primary completion estimated in April 2028. Even if successful, regulatory filing and approval would likely be several years beyond that, putting potential commercialization in the early 2030s at the earliest.

VIR-5818 Updated Nov 6

What to watch

The next catalyst for VIR-5818 is a data update at a future scientific conference, with no specific date announced. The program is being slowed by FDA-requested dose-optimization backfill cohorts under Project Optimus. Vir's near-term stock-moving catalysts are the Phase 3 ECLIPSE 1 hepatitis delta readout (expected Q4 2026) and VIR-5500 pivotal trial initiation (2027), not VIR-5818.

Bull case
  • Initial Phase 1 data (Jan 2025) showed encouraging safety with no dose-limiting cytokine release syndrome (CRS), a key differentiator versus unmasked T-cell engagers.
  • Tumor shrinkage was observed in heavily pretreated patients, including deep responses in MSS colorectal cancer, a tumor type traditionally resistant to immunotherapy.
  • The PRO-XTEN dual-masking technology is designed to enable tumor-specific TCE activation, potentially offering a best-in-class safety/efficacy profile versus other HER2-targeted T-cell engagers.
Bear case
  • VIR-5818 is an early Phase 1/2 asset with no specific near-term catalyst; primary completion is not until April 2028 after being pushed back from August 2027.
  • The program is being slowed by FDA Project Optimus dose-optimization requirements, requiring additional backfill cohorts before a data update can be provided.
  • The HER2-targeted therapy space is intensely competitive, with approved drugs like Enhertu (trastuzumab deruxtecan), Herceptin, Kadcyla, and multiple other bispecific antibodies in development.
● neutral
Impact
PhasePhase 1
Time to marketVIR-5525 is in Phase 1 dose escalation with no efficacy data yet. If successful through Phase 1, Phase 2 and potentially registrational trials would follow, meaning commercial launch is likely 5+ years away under typical timelines.

VIR-5525 sar 446368 Updated Nov 6

What to watch

VIR-5525 is still in Phase 1 dose escalation with no efficacy data or binary catalyst on the calendar. The next meaningful event would be initial safety/efficacy data at a future scientific conference, but management has not guided to a specific timeline. Vir's near-term stock-moving catalysts are elsewhere: the ECLIPSE Phase 3 hepatitis delta topline (Q4 2026) and VIR-5500's progression toward pivotal trials. VIR-5525 is a watch-and-wait program for now.

Bull case
  • Uses the same PRO-XTEN dual-masked TCE platform as VIR-5500, which received FDA Fast Track designation and a global Astellas collaboration, providing platform validation.
  • Targets EGFR, a well-validated oncology target expressed across multiple large solid tumor types (NSCLC, CRC, HNSCC, cSCC), offering a broad addressable market.
  • Dual-masked design is intended to reduce off-target toxicity (cytokine release syndrome) and expand the therapeutic index versus unmasked TCEs.
Bear case
  • Still in Phase 1 dose escalation with no efficacy data reported yet, meaning clinical proof-of-concept is years away.
  • EGFR is a well-established but highly competitive target with multiple approved therapies (EGFR TKIs, cetuximab, etc.) and other bispecific T-cell engagers in development.
  • As Vir's third TCE program (after VIR-5500 and VIR-5818), it may receive less pipeline priority and resource allocation.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Oct 6, 2026VIR-5500Fast Track−2.2%−9.9%

Clinical trials

8 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
tobevibartA Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionPhase 3Active not recruiting124Dec 31, 2026
tobevibartA Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtidePhase 3Active not recruiting150Dec 2026
tobevibartA Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionPhase 2Active not recruiting100Nov 2026
elebsiranStudy to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)Phase 2Completed150Aug 5, 2026
elebsiranStudy of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionPhase 2Completed244Mar 16, 2026
elebsiranInvestigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV PatientsPhase 2Completed86Jul 16, 2025
elebsiranStudy of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionPhase 2Completed · results84Mar 25, 2024
elebsiranStudy to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) InfectionPhase 2Completed · results91Jul 4, 2023